<DOC>
	<DOCNO>NCT00105313</DOCNO>
	<brief_summary>For primary objective , determine MTD examine clinical response immune cell population determine OBD , describe safety tolerability MEDI-507 . For secondary objective look antitumor activity MEDI 507 , PK , serum concentration , immunogenicity MEDI-507 , well time course depletion recovery CD2 positive total T-Cell population .</brief_summary>
	<brief_title>Study Evaluate MEDI-507 Patients With CD2-Positive Lymphoma/Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<criteria>Individuals may eligible study 18 year age older : Have one follow type TCell Lymphoproliferative disorder Cutaneous Tcell Lymphoma ( CTCL ) , Peripheral Tcell Lymphoma ( PCTL ) , Large Cell Lymphoma ( LGL ) , Adult Tcell Lymphoma ( ATL ) . Patients disease resistant refractory frontline therapy , except ATL patient standard therapy . At least 30 % tumor cell must CD2 positive . Karnofsky Performance status great equal 70 % ( able care ; unable carry normal activity active work ) . At least 3 week must pass since prior systemic cytotoxic chemotherapy , prolong cytolytic steroid therapy major surgery , treatmentrelated toxicity must resolve prior first MEDI507 administration ( except thrombocytopenia ) . Have prior treatment MEDI507 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>